Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
20 mai 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
Digital Health for Global Obesity Market Analysis Report 2024-2030, Featuring MyFitnessPal, Teladoc, FitnessKeeper, PlateJoy, Tempus, Fitbit, Noom, WellDoc, Sidekick Health and BioAge Labs
14 mai 2024 08h32 HE
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Digital Health For Obesity Market Size, Share & Trends Analysis Report By Component (Hardware, Software, Services), By End-use (Patients, Providers,...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
14 mai 2024 07h57 HE
|
ZyVersa Therapeutics
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
13 mai 2024 16h00 HE
|
Fractyl Health, Inc.
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
08 mai 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
07 mai 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
02 mai 2024 08h30 HE
|
Elevai Labs Inc.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
01 mai 2024 09h00 HE
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Global Anti-obesity Medication Market Trends Analysis Report 2024-2030: Social Media Influences and Strategic Partnerships, Mergers, Acquisitions, and Collaborations Shaping the Landscape
11 avr. 2024 11h14 HE
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-obesity Medication Market Size, Share & Trends Analysis Report" report has been added to ResearchAndMarkets.com's offering.The global...
UMeWorld to Debut the World's First & Only Weight Loss Cooking Oil in the US
09 avr. 2024 08h00 HE
|
UMeWorld Limited
MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) is excited to announce that the company has secured an exclusive license to use proprietary enzymatic technologies to...